Efficacy and Field Safety of the Second‐Generation, Highly Selective <scp>JAK1</scp> Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo‐Controlled Clinical Trial in Client‐Owned Dogs

Faris Jirjis, Timothy J. Kowalski, Robin C. Lynn, Lindsey Overbey, Qi Cao, Matthew Stock, Inka Kuhlmann

Open source

DOI: 10.1111/vde.70106
Published: 2026-09-17
Container: Veterinary Dermatology
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/vde.70106,
  title = {Efficacy and Field Safety of the Second‐Generation, Highly Selective
                    <scp>JAK1</scp>
                    Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo‐Controlled Clinical Trial in Client‐Owned Dogs},
  author = {Faris Jirjis and Timothy J. Kowalski and Robin C. Lynn and Lindsey Overbey and Qi Cao and Matthew Stock and Inka Kuhlmann},
  year = {2026},
  journal = {Veterinary Dermatology},
  doi = {10.1111/vde.70106},
  url = {https://doi.org/10.1111/vde.70106}
}

RIS

TY  - JOUR
TI  - Efficacy and Field Safety of the Second‐Generation, Highly Selective
                    <scp>JAK1</scp>
                    Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo‐Controlled Clinical Trial in Client‐Owned Dogs
AU  - Faris Jirjis
AU  - Timothy J. Kowalski
AU  - Robin C. Lynn
AU  - Lindsey Overbey
AU  - Qi Cao
AU  - Matthew Stock
AU  - Inka Kuhlmann
PY  - 2026
JO  - Veterinary Dermatology
DO  - 10.1111/vde.70106
UR  - https://doi.org/10.1111/vde.70106
ER  -

APA

Jirjis, F., Kowalski, T. J., Lynn, R. C., Overbey, L., Cao, Q., Stock, M., & Kuhlmann, I. (2026). Efficacy and Field Safety of the Second‐Generation, Highly Selective <scp>JAK1</scp> Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo‐Controlled Clinical Trial in Client‐Owned Dogs. Veterinary Dermatology. https://doi.org/10.1111/vde.70106

Source records

crossref · retrieved 2026-09-25T12:04:49.806Z